<SEC-DOCUMENT>0001193125-25-113024.txt : 20250506
<SEC-HEADER>0001193125-25-113024.hdr.sgml : 20250506
<ACCEPTANCE-DATETIME>20250505202910
ACCESSION NUMBER:		0001193125-25-113024
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20250505
FILED AS OF DATE:		20250506
DATE AS OF CHANGE:		20250505

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		25914776

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 32, SUITE 32.07 AUSTRALIA SQUARE
		STREET 2:		264 GEORGE STREET
		CITY:			SYDNEY,
		STATE:			C3
		ZIP:			NSW 2000
		BUSINESS PHONE:		612 8315 7003

	MAIL ADDRESS:	
		STREET 1:		LEVEL 32, SUITE 32.07 AUSTRALIA SQUARE
		STREET 2:		264 GEORGE STREET
		CITY:			SYDNEY,
		STATE:			C3
		ZIP:			NSW 2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d72890d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Date as May 5, 2025 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-35428 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact
Name as Specified in its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#146;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 32, Australia Square </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>264 George Street, Sydney </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NSW 2000, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 20-F&#8194;&#9746;&#8195;&#8195;&#8195;Form 40-F&#8194;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&#8194;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&#8194;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the
Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&#8194;&#9744;&#8195;&#8195;&#8195;No&#8194;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><A HREF="d72890dex991.htm">Immutep&#146;s Efti in Combination with KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (pembrolizumab)
 Drives Strong Overall Survival in Head and Neck Cancer with CPS &lt;1 </A></P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: May 5, 2025 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d72890dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g72890g21i59.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</DIV>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep&#146;s Efti in Combination with KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (pembrolizumab) Drives </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Strong Overall Survival in Head and Neck Cancer with CPS &lt;1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Complementary nature of these two immunotherapies leads to excellent
<FONT STYLE="white-space:nowrap">17.6-month</FONT> median Overall Survival in head and neck cancer patients with <FONT STYLE="white-space:nowrap">PD-L1</FONT> CPS &lt;1 </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Mature overall survival data builds on encouraging high response rates with multiple complete responses
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Patients with CPS &lt;1 represent a high unmet medical need and have no available treatment options without
chemotherapy </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Meeting with FDA has now been requested to discuss next steps including potential paths to approval
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SYDNEY, AUSTRALIA &#150; May 05, </B><B>2025 &#150;</B> Immutep Limited (ASX: IMM; NASDAQ: IMMP) (&#147;Immutep&#148; or &#147;the
Company&#148;), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces an excellent median Overall Survival (OS) of 17.6 months has been achieved in Cohort B of the
<FONT STYLE="white-space:nowrap">TACTI-003</FONT> <FONT STYLE="white-space:nowrap">(KEYNOTE-C34)</FONT> Phase IIb trial. This part of the Phase II study evaluates eftilagimod alfa (efti) in combination with MSD&#146;s (Merck&nbsp;&amp; Co., Inc.,
Rahway, NJ, USA) <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (pembrolizumab) as first line therapy in recurrent/metastatic head
and neck squamous cell carcinoma (1L HNSCC) patients with <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression below 1 (Combined Positive Score [CPS] &lt;1). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The mature <FONT STYLE="white-space:nowrap">17.6-months</FONT> median OS in evaluable patients (N=31) with a data
<FONT STYLE="white-space:nowrap">cut-off</FONT> of 31<SUP STYLE="font-size:75%; vertical-align:top"> </SUP>March 2025 compares favourably to historical results from the two current
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> approaches for 1L HNSCC patients with CPS &lt;1 including <FONT STYLE="white-space:nowrap">10.7-months</FONT> from cetuximab + chemotherapy and <FONT
STYLE="white-space:nowrap">11.3-months</FONT> from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy + chemotherapy, as well as <FONT STYLE="white-space:nowrap">7.9-months</FONT> from <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> monotherapy.<SUP STYLE="font-size:75%; vertical-align:top">1,2</SUP> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patients with CPS &lt;1 in 1L HNSCC represent a treatment population with high unmet medical need. Up to 20% of 1L HNSCC patients have CPS &lt;1 and despite
immunotherapy&#146;s progress in fighting cancer, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy alone (without chemotherapy) is only approved for patients who express
<FONT STYLE="white-space:nowrap">PD-L1</FONT> (CPS <U>&gt;</U>1). Additionally, all available treatment options for patients with <FONT STYLE="white-space:nowrap">PD-L1</FONT> CPS &lt;1 include chemotherapy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Importantly, efti in combination with pembrolizumab continues to be well-tolerated with no new safety signals. This safety and mature OS data build on the
encouraging high overall response rate with multiple complete responses achieved through combining these powerful immunotherapies in 1L HNSCC patients with CPS &lt;1.<SUP STYLE="font-size:75%; vertical-align:top">3</SUP> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are excited to see this strong survival benefit for head and neck cancer patients with such cold tumors. Combining these two complementary
immunotherapies has led to a <FONT STYLE="white-space:nowrap">7-fold</FONT> increase in response rates and a more than doubling of median overall survival as compared to historical results from <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> monotherapy. Driving durable responses that translate into clinically meaningful survival holds tremendous promise for these patients in need of more tolerable and efficacious therapies,&#148; said
Marc Voigt, CEO of Immutep. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;There is a high unmet need in 1L HNSCC patients with cold tumors and <FONT STYLE="white-space:nowrap">PD-L1</FONT> CPS
&lt;1, due to the lack of an approved immunotherapy-only treatment regimen and a lack of competitor trials with chemotherapy-free approaches targeting this patient population. Given the strength of the efficacy and safety results generated to date
with efti in combination with pembrolizumab, we will meet with regulators to discuss next steps and potential paths to approval,&#148; added Mr. Voigt. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g72890g21i59.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</DIV>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Next Steps </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efti has Fast Track designation in 1L HNSCC
and Immutep has requested a meeting with the U.S. Food and Drug Administration (FDA) to discuss next steps including potential paths to approval for 1L HNSCC with <FONT STYLE="white-space:nowrap">PD-L1</FONT> CPS &lt;1. Patient follow up, data
collection, cleaning and analysis continue for <FONT STYLE="white-space:nowrap">TACTI-003,</FONT> and the Company plans to provide a further update later this year. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Eftilagimod Alfa (efti) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efti is Immutep&#146;s
proprietary soluble <FONT STYLE="white-space:nowrap">LAG-3</FONT> protein and MHC Class&nbsp;II agonist that stimulates both innate and adaptive immunity for the treatment of cancer. As a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">first-in-class</FONT></FONT> antigen presenting cell (APC) activator, efti binds to MHC (major histocompatibility complex) Class&nbsp;II molecules on APC leading to activation and proliferation of CD8+ cytotoxic T cells,
CD4+ helper T cells, dendritic cells, NK cells, and monocytes. It also upregulates the expression of key biological molecules like <FONT STYLE="white-space:nowrap">IFN-</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT> and CXCL10 that further
boost the immune system&#146;s ability to fight cancer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efti is under evaluation for a variety of solid tumours including
<FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), and metastatic breast cancer. Its favourable safety profile enables various combinations, including with <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-[L]1</FONT></FONT> immunotherapy and/or chemotherapy. Efti has received Fast Track designation in first line HNSCC and in first line NSCLC from the United States Food and Drug
Administration (FDA). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Immutep </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is a
late-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation
<FONT STYLE="white-space:nowrap">Gene-3</FONT> <FONT STYLE="white-space:nowrap">(LAG-3),</FONT> and its diversified product portfolio harnesses <FONT STYLE="white-space:nowrap">LAG-3&#146;s</FONT> ability to stimulate or suppress the immune
response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit www.immutep.com. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><I>1.</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Burtness, B. et al. Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous
Cell Carcinoma in <FONT STYLE="white-space:nowrap">KEYNOTE-048:</FONT> Subgroup Analysis by Programmed Death <FONT STYLE="white-space:nowrap">Ligand-1</FONT> Combined Positive Score. Journal of Clinical Oncology 2022 40:21, <FONT
STYLE="white-space:nowrap">2321-2332.</FONT> </I></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><I>2.</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Burtness B. et al. Abstract <FONT STYLE="white-space:nowrap">LB-258:</FONT> Efficacy of first-line (1L)
pembrolizumab by <FONT STYLE="white-space:nowrap">PD-L1</FONT> combined positive score &lt;1, <FONT STYLE="white-space:nowrap">1-19,</FONT> and </I>&#8805;<I></I><I>20 in recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma
(HNSCC): <FONT STYLE="white-space:nowrap">KEYNOTE-048</FONT> subgroup analysis. Cancer Res 15&nbsp;August 2020; 80 (16_Supplement): LB&#150;258.
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">https://doi.org/10.1158/1538-7445.AM2020-LB-258</FONT></FONT> </I></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><I>3.</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Forster M. et al., ESMO Immuno-Oncology 2024 - December 2024,
<FONT STYLE="white-space:nowrap">TACTI-003</FONT> Cohort B: Eftilagimod Alpha (Soluble <FONT STYLE="white-space:nowrap">LAG-3)</FONT> and Pembrolizumab in First-Line Recurrent or Metastatic Head<U></U>&nbsp;&amp; Neck Squamous Cell Carcinoma with
CPS &lt;1 </I></P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Investors/Media: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Catherine Strong, Sodali&nbsp;&amp; Co. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (0)406 759 268;
<U>catherine.strong@sodali.com</U> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Media: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chris Basta, VP, Investor Relations and Corporate Communications </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (631) 318 4000; <U>chris.basta@immutep.com</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This
announcement was authorised for release by the Board of Immutep Limited. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>, Level&nbsp;32, Australia Square, 264
George Street, Sydney NSW 2000, Australia </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g72890g21i59.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g72890g21i59.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M^$TSX7UX^-C?8Q!]I\SS_,'W,],9STXQ72>F>C 8&* "@ H * "@ H * "@
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ME@V?YT =QX0\0W/B"UN9;F.*-HG"@1@CMGN: '^)?%=OX>5(S&9KF096,'
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M-]Z6.%S]25H ROABJF34B0#@1_\ LU '6>(-"L]6TV=)($\\(3'(%&Y3VYH
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M?"EAL.=JE3[$,: -X]"* /"KNS33M<DM+L,8HIMK[>"5SU'X4 >C0> O#]S
MDT+SO&X#*PEX(_*@!Y^'FA#_ )^/^_O_ -:@!WC*VCL_ TEM%GRXA&BYZX#
M4 8OPP/[S4Q[1_\ LU '<:M?1:;I5S=3$!(T)^I[#\Z /*? ]N]QXKM64<1;
MI&]A@C^9% 'L= !0 4 <"= U/_A(#<_93Y/VG?NW#[N[.>M8<CYKGG^QG[2Y
MTGB6SN+[1S!;1[Y-X.,@5I-71U5HN4+(S_"6EWNFS7)NX#$'"[>0<]?2IIQ:
M,L/3E#<O>*;*XO\ 2EAM8_,D$@;&0.,'UIS5U8TK0<HV1!X3TZ[TZVN%NHO+
M+,"!D'M[44TTB</"4%9DOBJQN=0TR.&UB\QQ*&(R!Q@^M%1-JR'B(2G&R&>%
M-/NM.LIX[J(QLTF0,@Y&!Z44TX[BP\'!-,P=:T#4[K6+F>&U+1NV5.X<\?6L
MW%N1A4HS<[H[JW4I;QJPP0H!_*NA:([UHDCA]0T'4YM=FN([4F)IMP;<.F?K
M6$HMNYP3I2=2Z.['2MSO6QPESH&IOX@DN5M283<;PVX=-V<]:Y^1\US@E2G[
M2YW$L*7%N\,JAHY%*LI[@UT'H'EFI>"M8TR_:734>:%3F.2-@'7^N?I0!#+8
M>,;Z$V\\=_)&W57<[3]<GF@#H?!'AK5-(U26[O8%BC:$H!O!.25/;Z4 ;/C#
MPXVO6$9MR!=P',>XX# ]1^@H X.WTKQ=I>Z&U@O85)Y$394GUX.* .R\%V>N
M6K7;ZOYF)0I0RR;FR,Y[\=: $\6>#1K+F]LV6.\"X*G[L@'KZ&@#CHM+\7Z7
MF&WCOHU'\,3DK^AQ0!HZ9I?B^XU2TN;DW)CBE5F\^; QGG@GTH ZKQY_R*%U
M_O)_Z$* /--%T[5[QIIM(,GF0XW>7)L;G..X]* -&71?%NJNL5S%=R#/_+:3
MY1^9H [OPIX670+=Y)662\E #L.BC^Z* .DH * "@!JLKC*D$9(X]J $WH)!
M'N <C('?'^2* ([BZM[2,R7$R1(.K.P H ?%+'/&LD3K(C#(93D'\: (C>VJ
MW8M#<1BX(R(MPW$?2@18Z4#&"6/8CAUVOC:<]<],4 *717"D@,W09ZT  D0E
M@&!*G! [4 )YT>POO7:#@G/ .<?SH 4LH<(2 Q&0.Y'^30&HGG1[&?>NU<Y.
M>!CK0 V>Y@M8C+<2I%&.K.P H 1;NV:V%RLT9@QGS PVX]<T -@U"RNI-D%U
M#*X&=J."?TH E$L>P.&7:< '/!STH BGO[.V<)/=0Q.1D*[@']: ">_L[78)
M[J&+?]S>X&[Z4 6 05##D'H: &QRQRQB2-U=#T8'(- $5O?VETS+;W,4I7J$
M<''Y4 /^T0>4)?,783@-GC.<?SH Y_QY_P BC=?[R?\ H0H P/AA]_4_I'_[
M-0!Z)B@ H * "@ H R]+N85C:W,BB;SI?D)Y_P!8Q_E0!1N?MSSRZI;P(WDO
MA,N=S1KD, ,=^3U[+Z4 69F$>NK<W)'V4P 1,WW4?)W9]"1C\C0!/87%Q=Z>
MLL,<41WN-I4XVAB 1]0 ?QH AU-D:6%8Y4:19HRT(7YF^8<YZC Y_"@#7/W:
M ,'[,UQH^BVYW(<(<@<H1$Q!_ XH ="EW)?V5Y>1[)3(T0C'(1=C$G\2!^E
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MYH I>.8WD\)W*1HSL63 49/WA0!A?#2"6%]2\V)X\B/&Y2,_>H ] H * "@
&H * /__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
